FHIT gene abnormalities in both benign and malignant thyroid tumours

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 467-472

  Zou, M ^a   Shi, Y ^a   Farid, N R ^b   Al Sedairy, S T ^a   Paterson, M C ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Hemel Hempstead General Hospital   (United Kingdom)

Author keywords

FHIT; Fragile histidine triad; Thyroid neoplasm; Tumour suppressor gene

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE DELETION; GENE INSERTION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CANCER; THYROID TUMOR; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; BLOTTING, SOUTHERN; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033104711     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00370-0     Document Type: Article

References (36)

1. Farid N.R., Shi Y., Zou M.J. Molecular basis of thyroid cancer. Endocr Rev. 15:1994;202-232.
2. Wright P.A., Lemoine N.R., Mayall E.S., et al. Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br J Cancer. 60:1989;576-577.
3. Shi Y., Zou M., Schmidt H., et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res. 51:1991;2690-2693.
4. Grieco M., Santoro M., Berlingieri M.T., et al. PTC is a novel rearranged form of ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 60:1990;557-563.
5. Bongarzone I., Pierotti M.A., Monzini N., et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinomas. Oncogene. 4:1989;1457-1462.
6. Ito T., Seyama T., Mizuno T., et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 52:1992;1369-1371.
7. Zou M.J., Shi Y., Farid N.R. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab. 77:1993;1054-1058.
8. Zou M.J., Shi Y., Farid N.R. Frequent inactivation of the retinoblastoma gene in human thyroid carcinomas. Endocrine. 2:1994;193-198.
9. Tung W.S., Shevlin D.W., Bartsch D., Norton J.A., Wells S.A., Goodfellow P.J. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinogen. 15:1996;5-10.
10. Shi Y., Zou M.J., Farid N.R., Al-Sedairy S.T. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br J Cancer. 74:1996;1336-1341.
11. Farid N.R., Zou M.J., Shi Y. Genetics of follicular thyroid cancer. Endocrinol Metab Clin North Am. 24:1995;865-883.
12. Matsuo K., Tang S.H., Fagin J.A. Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. Mol. Endocrinol. 5:1991;1873-1879.
13. Herrmann M.A., Hay I.D., Bartelt D.H., et al. Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. J Clin Invest. 88:1991;1596-1604.
14. Ohta M., Inoue H., Cotticelli M.G., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:1996;587-597.
15. Seraphin B. The HIT protein family: a new family of proteins present in prokaryotes, yeast and mammals. J DNA Sequencing & Mapping. 3:1992;177-179.
16. Huang Y., Garrison P.N., Barnes L.D. Cloning of the Schizosaccharomyces pombe gene encoding diadenosine 5′-5‴-P1,P4-tetraphosphate (Ap4A) asymmetrical hydrolase: sequence similarity with the histidine triad (HIT) family. Biochem J. 312:1995;925-932.
17. Barnes L.D., Garrison P.N., Siprashvili Z., et al. FHIT, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry. 35:1996;11529-11535.
18. Weinmann-Dorsch C., Grummt I., Albert W., et al. Drastic rise of intracellular adenosine (5′) tetraphospho (5′) adenosine correlates with onset of DNA synthesis in eukaryotic cells. Eur J Biochem. 138:1984;179-185.
19. 4A binding protein by photoaffinity labeling. Biochemistry. 33:1994;14601-14607.
20. Sozzi G., Veronese M.L., Negrini M., et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell. 85:1996;17-26.
21. Negrini M., Monaco C., Vorechovsky I., et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 56:1996;3173-3179.
22. Mao L., Fan Y.-H., Lotan R., Hong W.K. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res. 56:1996;5128-5131.
23. Sozzi G., Alder H., Tornielli S., et al. Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res. 56:1996;2472-2474.
24. Hermanek P, Sobin LH. eds. TNM Classification of Malignant Tumors. Berlin, Springer, 1987 33-35.
25. Zou M.J., Shi Y., Al-Sedairy S., Farid N.R. High levels of Nm23 gene expression in advanced stage of thyroid carcinomas. Br J Cancer. 68:1993;385-388.
26. Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:1989;874-879.
27. Zou M.J., Shi Y., Al-Sedairy S.T., Hussain S.S., Farid N.R. The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis. Cancer. 76:1995;314-318.
28. Druck T., Hadaczek P., Fu T.-B., et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 57:1997;504-512.
29. Fong K.M., Biesterveld E.J., Virmani A., et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 57:1997;2256-2267.
30. Sozzi G., Tornielli S., Tagliabue E., et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 57:1997;5207-5212.
31. Virgilio L., Shuster M., Gollin S.M., et al. FHIT alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA. 93:1996;9770-9775.
32. McIver B, Grebe SKG, Hay ID, Wang L, Smith DI, Eberhardt NL. The fragile histidine triad gene in follicular thyroid cancer. 79th Annual Meeting of Endocrine Society, Minneapolis, U.S.A. Abstract No. p.3-12, p.439.
33. Crebe S.K.G., McIver B., Hay I.D., et al. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab. 82:1997;3684-3691.
34. Tung W.S., Shevlin D.W., Kaleem Z., Tribune D.J., Wells S.A., Goodfellow P.J. Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer. 19:1997;43-51.
35. Ward L.S., Brenta G., Medvedovic M., Fagin J.A. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab. 83:1998;525-530.
36. Panagopoulos I., Pandis N., Thelin S., et al. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 56:1996;4871-4875.